CL
CLBT.US Cellebrite DI
- Market cap
- USD 2.90B
- P/E
- 46.1x
- P/B
- 5.09x
- ROE
- 10.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CLBT.US undervalued?
Graham numberThe Graham number of Cellebrite DI cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cellebrite DI fundamental analysis
No fundamental analysis for Cellebrite DI yet.
Cellebrite DI stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cellebrite DI
Cellebrite DI Ltd. develops software and services for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company provides a platform of software solutions used to access, collect, review, extract, decode, decrypt, analyze, share and manage digital evidence across the investigative lifecycle for a range of investigations, such as child exploitation, homicide, anti-terror, border control, sexual crimes, organized crime…
Full company profileCellebrite DI financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Cellebrite DI annual financial statements
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 172M | 195M | 246M | 271M | 325M | 401M | 476M | 545M |
| Gross Profit | 136M | 157M | 204M | 220M | 272M | 339M | 401M | 444M |
| Operating Income | -1.52M | 9.22M | 13.8M | 1.04M | 33.2M | 56.9M | 66.5M | 58.2M |
| EBITDA | 5.62M | 17.3M | 89.5M | 130M | -65.4M | -265M | 103M | 97.9M |
| Net Income | -1.88M | 5.78M | 71.4M | 121M | -81.1M | -283M | 78.3M | 58.6M |
| EPS | -0.01 | 0.03 | 0.44 | 0.62 | -0.43 | -1.35 | 0.31 | 0.23 |
| Balance Sheet | ||||||||
| Total Assets | 280M | 364M | 340M | 403M | 533M | 691M | 939M | 1.07B |
| Total Liabilities | 221M | 301M | 413M | 329M | 499M | 355M | 455M | 489M |
| Shareholders' Equity | 58.8M | 63.8M | -73.3M | 73.9M | 34.2M | 336M | 484M | 579M |
| Cash & Short-term Investments | 200M | 238M | 182M | 184M | 303M | 447M | 437M | 484M |
| Total Debt | - | - | - | 15.4M | 14.1M | 11.0M | 22.7M | 23.4M |
| Cash Flow | ||||||||
| Operating Cash Flow | 16.1M | 66.5M | 36.1M | 20.6M | 102M | 132M | 169M | 125M |
| Capital Expenditure | 6.21M | 6.18M | 8.11M | 9.09M | 7.92M | 10.6M | 13.2M | 14.5M |
| Free Cash Flow | 9.92M | 60.3M | 27.9M | 11.5M | 94.1M | 122M | 156M | 111M |
| Ratios | ||||||||
| ROE | -3.2% | 9.1% | - | 163.5% | -237.1% | -84.2% | 16.2% | 10.1% |
| ROA | -0.7% | 1.6% | 21.0% | 30.0% | -15.2% | -41.0% | 8.3% | 5.5% |
| Net Profit Margin | -1.1% | 3.0% | 29.0% | 44.6% | -24.9% | -70.5% | 16.5% | 10.8% |
| Debt to Equity | - | - | - | 0.21x | 0.41x | 0.03x | 0.05x | 0.04x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Cellebrite DI dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | USD 100M | 0.62 | 140.1% |
| 2020 | USD 10.0M | 0.05 | 173.0% |
| 2019 | USD 25.0M | 0.13 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Cellebrite DI
- Insiders 44.72%
- Institutions 47.98%
- Public & others 7.30%
- Shares outstanding 251M
- Free float 98.8M
Top funds holding CLBT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| American Funds SMALLCAP World A | 4.06M | 1.61% | 0.00% | Sep 2026 |
| Central Securities Corporation | 1.50M | 0.60% | +15.38% | Sep 2026 |
| Strategic Advisers U.S. Total Stock | 1.47M | 0.58% | -28.93% | Sep 2026 |
| Fidelity Stock Selector Small Cap | 1.30M | 0.52% | 0.00% | Aug 2026 |
| Janus Henderson Venture D | 1.14M | 0.45% | 0.00% | Sep 2026 |
| Fidelity Advisor Small Cap I | 996K | 0.40% | 0.00% | Aug 2026 |
| iShares Core MSCI EAFE ETF | 942K | 0.38% | 0.00% | Oct 2026 |
| Brown Capital Mgmt Intl Sm Co Inv | 907K | 0.36% | -4.43% | Sep 2026 |
| Fidelity Series Small Cap Opps | 807K | 0.32% | -3.51% | Aug 2026 |
| Vanguard International Explorer Inv | 518K | 0.21% | -13.08% | Sep 2026 |
| WisdomTree Cloud Computing ETF - USD Acc | 497K | 0.20% | -2.37% | Oct 2026 |
| iShares MSCI EAFE Small-Cap ETF | 448K | 0.18% | 0.00% | Oct 2026 |
| ClearBridge Small Cap Growth A | 442K | 0.18% | 0.00% | Sep 2026 |
| BNY Mellon VIF Small Cap Port Initl | 415K | 0.17% | 0.00% | Sep 2026 |
| WisdomTree Cloud Computing ETF | 407K | 0.16% | -2.07% | Oct 2026 |
| BNY Mellon Sm Cp Val I | 344K | 0.14% | 0.00% | Sep 2026 |
| Mediolanum BB Innovative Thematic Opps L | 310K | 0.12% | 0.00% | Jun 2026 |
| LKCM Small Cap Equity Instl | 301K | 0.12% | 0.00% | Sep 2026 |
| Carillon Eagle Small Cap Growth A | 284K | 0.11% | -29.62% | Sep 2026 |
| iShares MSCI Israel ETF | 267K | 0.11% | 0.00% | Oct 2026 |
Top institutions holding CLBT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| True Wind Capital Management, L.P. | 13.9M | 5.51% | 0.00% | Jun 2026 |
| Voss Capital LLC | 11.4M | 4.55% | +18.26% | Jun 2026 |
| Pertento Partners LLP | 8.00M | 3.18% | +20.15% | Jun 2026 |
| Phoenix Financial Ltd | 6.18M | 2.46% | +47.83% | Jun 2026 |
| FMR Inc | 5.97M | 2.38% | -29.66% | Jun 2026 |
| BlackRock Inc | 5.68M | 2.26% | +70.20% | Jun 2026 |
| Nine Ten Capital Management LLC | 4.13M | 1.64% | +19.83% | Jun 2026 |
| Artisan Partners Limited Partnership | 3.27M | 1.30% | +49.45% | Jun 2026 |
| Wellington Management Company LLP | 3.05M | 1.21% | +93.73% | Jun 2026 |
| Clal Insurance Enterprises Holdings Ltd | 2.77M | 1.10% | -12.61% | Jun 2026 |
| T. Rowe Price Investment Management,Inc. | 2.38M | 0.95% | -28.20% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 2.19M | 0.87% | +5.41% | Jun 2026 |
| Renaissance Technologies Corp | 2.15M | 0.86% | -24.83% | Jun 2026 |
| Capital World Investors | 2.11M | 0.84% | +880.35% | Jun 2026 |
| Capital Research & Mgmt Co - Division 3 | 2.06M | 0.82% | -9.53% | Jun 2026 |
| Progeny 3, Inc. | 2.00M | 0.80% | +77.28% | Jun 2026 |
| Portolan Capital Management, LLC | 1.93M | 0.77% | -11.39% | Jun 2026 |
| Weiss Asset Management LP | 1.92M | 0.77% | +1.24% | Jun 2026 |
| Ashford Capital Management Inc | 1.78M | 0.71% | +0.87% | Jun 2026 |
| Bank of New York Mellon Corp | 1.74M | 0.69% | +30.78% | Jun 2026 |
Cellebrite DI company profile
- Company name
- Cellebrite DI
- Ticker
- CLBT.US
- ISIN
- IL0011794802
- Exchange
- USA Stocks
- Listed since
- Aug 31, 2021
- Sector
- Technology
- Industry
- Software
- Employees
- 1,285
- Fiscal year end
- December
- Address
- 94 Shlomo Shmelzer Road, Petah Tikva, Israel, 4970602
- Phone
- 972 73 394 8000
- Website
- cellebrite.com
About Cellebrite DI
Cellebrite DI Ltd. develops software and services for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company provides a platform of software solutions used to access, collect, review, extract, decode, decrypt, analyze, share and manage digital evidence across the investigative lifecycle for a range of investigations, such as child exploitation, homicide, anti-terror, border control, sexual crimes, organized crime, human trafficking, corporate security, and intellectual property theft, as well as financial crimes, including those involving cryptocurrency. It also offers Inseyets, digital forensics software that collects and reviews digital evidence from various digital sources when conducting legally sanctioned investigations; Guardian Forensics, an evidence management solution which enables customers to manage their digital forensics workflows, and to store, share and review digital evidence; Guardian Collaborate, a digital evidence sharing tool; and Guardian Investigate, a case management and AI-powered analytics solution. In addition, it provides Cellebrite Pathfinder, which reduces the time spent manually reviewing digital evidence and enables actionable insights into a range of crime types; Corellium Falcon for conducting mobile vulnerability research, exploit introspection, and malware analysis; and Corellium Viper for mobile application penetration testing capabilities. Further, the company offers professional services, such as training and certification services, and advanced services. It serves federal, state, and local agencies, as well as corporations and service providers. The company is headquartered in Petah Tikva, Israel.
Cellebrite DI management
10- Mr. David BarterChief Financial Officer · born 1972
- Mr. Thomas E. HoganAdvisor · born 1959
- Mr. Marcus JewellGlobal Chief Revenue Officer · born 1973
- Mr. Shiven RamjiCEO & Director
- Mr. Christopher WadeChief Technology Officer · born 1984
- Ms. Sigalit ShavitChief Information Officer · born 1968
- Andrew KramerVP of Investor Relations & Treasury
- Ms. Holly B. Windham Esq., J.D.General Counsel & Chief Compliance Officer · born 1966
- Mr. David Nicholas GeeChief Marketing Officer · born 1967
- Ms. Zohar Tadmor-EilatChief People Officer · born 1972